Dose Response Relationship Between Fat Ingestion and Metabolism (AFDR)
Investigating the Effect of Acute Fat Ingestion on Glucose Metabolism in Young Healthy Adults: a Dose Response Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kirsten E Bell, Ph.D.
- Phone Number: 24872 905 525 9140
- Email: bellke3@mcmaster.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 3X3
- McMaster University, Ivor Wynne Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI between 18.5 and 30.0 kg/m2
- Weight stable for the past 6 months (± 2kg)
- VO2max values within a below average to above average range (38-50 mL/kg and 35-47 mL/kg for 18-25 year old males and females respectively. 35-48 mL/kg and 34-45 mL/kg for 26-35 year old males and females respectively)
- Fasting blood glucose <6.0 mM
- Resting blood pressure <140/90 mmHg
- Taking second generation oral contraceptives (females only)
Exclusion Criteria:
- Smoking
- Diabetes, cancer, or other metabolic disorders
- Cardiac or gastrointestinal problems
- Infectious disease
- Barium swallow or nuclear medicine scan in the previous 3 weeks
- Follow a strict vegan diet
- Pregnant or breastfeeding (females only)
- Diagnosis of polycystic ovary syndrome (females only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 20% fat meal
This meal will contain 15 kcal/kg of body weight and consist of 20% fat, 65% carbohydrates, and 15% protein.
|
Provided to participants once throughout duration of study, contains 20% fat
|
|
Experimental: 40% fat meal
This meal will contain 15 kcal/kg of body weight and consist of 40% fat, 45% carbohydrates, and 15% protein.
|
Provided to participants once throughout duration of study, contains 40% fat
|
|
Experimental: 60% fat meal
This meal will contain 15 kcal/kg of body weight and consist of 60% fat, 25% carbohydrates, and 15% protein.
|
Provided to participants once throughout duration of study, contains 60% fat
|
|
Experimental: 80% fat meal
This meal will contain 15 kcal/kg of body weight and consist of 80% fat, 5% carbohydrates, and 15% protein.
|
Provided to participants once throughout duration of study, contains 80% fat
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose tolerance
Time Frame: Two hours (taking place following the 4-hour postprandial period)
|
A 2-hour intravenous glucose tolerance test will be performed 4-hours after meal consumption
|
Two hours (taking place following the 4-hour postprandial period)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose and lipid metabolites
Time Frame: During the 4-hour postprandial period
|
Postprandial availability of glucose (mM)
|
During the 4-hour postprandial period
|
|
Glucose and lipid metabolites
Time Frame: During the 4-hour postprandial period
|
Postprandial availability of insulin (µIU/mL)
|
During the 4-hour postprandial period
|
|
Glucose and lipid metabolites
Time Frame: During the 4-hour postprandial period
|
Postprandial availability of total cholesterol (mmol/L)
|
During the 4-hour postprandial period
|
|
Glucose and lipid metabolites
Time Frame: During the 4-hour postprandial period
|
Postprandial availability of low-density lipoprotein (mmol/L)
|
During the 4-hour postprandial period
|
|
Glucose and lipid metabolites
Time Frame: During the 4-hour postprandial period
|
Postprandial availability of high-density lipoprotein (mmol/L)
|
During the 4-hour postprandial period
|
|
Glucose and lipid metabolites
Time Frame: During the 4-hour postprandial period
|
Postprandial availability of non-esterified fatty acids (mmol/L)
|
During the 4-hour postprandial period
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hunger hormones
Time Frame: During the 4-hour postprandial period
|
Postprandial concentration of ghrelin (pmol/L)
|
During the 4-hour postprandial period
|
|
Hunger hormones
Time Frame: During the 4-hour postprandial period
|
Postprandial concentration of leptin (pmol/L)
|
During the 4-hour postprandial period
|
|
Hunger hormones
Time Frame: During the 4-hour postprandial period
|
Postprandial concentration of adiponectin (pmol/L)
|
During the 4-hour postprandial period
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 16153
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Tolerance Impaired
-
NCT01845259UnknownImpaired Glucose Tolerance Associated With Drugs
-
NCT04280991CompletedObesity | Insulin Resistance | Impaired Glucose Tolerance in Obese
-
NCT01395602CompletedBody Weight | Impaired Glucose Tolerance in Obese
-
NCT01588418CompletedDiabetes | Impaired Glucose Tolerance (IGT)
-
NCT03398356CompletedPreDiabetes | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)
-
NCT03195400CompletedT2D | IGT - Impaired Glucose Tolerance
-
NCT00319189CompletedRenal Transplant Recipients | Posttransplant Diabetes Mellitus | Posttransplant Impaired Glucose Tolerance
-
NCT02969798RecruitingDiabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)
-
NCT06571279CompletedPrediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Clinical Trials on 20% fat meal
-
NCT04061369TerminatedObesity | Overweight | Body Weight
-
NCT02521779Completed
-
NCT03839641CompletedDiabetes Mellitus, Type 2
-
NCT01995110CompletedObesity | Nutritional Intervention
-
NCT07278063Not yet recruitingType 1 Diabetes Mellitus | Menstrual Cycle | Dietary Fat | Glycemic Variability | Postprandial Glucose | Sex Characteristics
-
NCT02273427Completed
-
NCT02886169CompletedCardiovascular Diseases
-
NCT00766623CompletedCardiovascular Disease | Endothelial Dysfunction
-
NCT04887610CompletedDietary Exposure | Ischemic Preconditioning